Light therapy for advanced lung tumors using 5-ALA
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new light-based therapy (photodynamic therapy or PDT) using a drug called 5-ALA to treat advanced lung tumors. The treatment is delivered through a thin tube inserted into the lung (bronchoscopy), aiming to shrink tumors that can't be removed with surgery and haven't responded to other treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced or terminal lung cancer (primary or metastatic) and standard treatments have stopped working or aren't an option.
- Your lung tumor is 3 cm or smaller and can be seen clearly on a CT scan.
- You are in generally good health (able to do most daily activities on your own).
- Your tumor is not in the central part of your lung, and it is not small cell or non-solid cancer.
- You haven't had chemotherapy in the last 4 weeks or radiation to the treatment area before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new light-activated therapy (interstitial photodynamic therapy) after palliative radiation to shrink inoperable airway tumors and improve breathing. It is for people with solid cancers that block the airway from the outside and cannot be removed with surgery.
This trial tests a special dye that helps surgeons see tumors more clearly during surgery, followed by a light therapy to destroy any remaining cancer cells. It is for people with advanced or returning colorectal cancer who are already scheduled for surgery.
This Phase 1 trial tests padeliporfin, a light-activated medicine, delivered to lung tumors using robotic bronchoscopy. It may help people with small, peripheral lung cancer lesions by targeting the tumor without open surgery.
This trial compares two surgical techniques for removing malignant brain tumors: one using a special dye (5-ALA) that makes tumor cells glow under a blue light, versus the standard white light surgery. The goal is to see if the dye-guided approach helps surgeons remove more of the tumor safely.
This trial tests a new treatment that uses a light-activated drug (ASP-1929) plus an immunotherapy (cemiplimab) for people with advanced non-small cell lung cancer that has not responded to other treatments. The light-activated drug is delivered directly to the tumor through a thin fiber or external light, aiming to kill cancer cells while boosting the immune system.
This trial tests a low-cost approach to find and treat early mouth cancers or precancerous spots using a special light-activated drug (photodynamic therapy). The goal is to destroy the abnormal cells while sparing healthy tissue.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.